Methionine gamma lyase from Clostridium sporogenes increases the anticancer effect of doxorubicin in A549 cells and human cancer xenografts

Summary: The anti-cancer efficacy of methionine γ-lyase (MGL) from Clostridium sporogenes (C. sporogenes) is described. MGL was active against cancer models in vitro and in vivo. The calculated EC50 values for MGL were 4.4 U/ml for A549, 7.5 U/ml for SK-BR3, 2.4 U/ml for SKOV3, and 0.4 U/ml for MCF7 cells. The combination of doxorubicin (DOX) and MGL was more effective for A549 human lung cancer growth inhibition than either agent alone in vitro and in vivo. MGL reduced the EC50 of doxorubicin from 35.9 μg/mL to 0.01–0.265 μg/mL. The growth inhibitory effect of DOX + MGL on A549 xenografts in vivo was reflective of the results obtained in vitro. The inhibition rate of tumor growth in the combined arm was 57%, significantly higher than that in the doxorubicin (p = 0.033)-alone arm. © 2018 Springer Science+Business Media, LLC, part of Springer Nature

Pokrovsky V.S. 1, 2 , Yu Anisimova N. , Zh Davydov D. , Bazhenov S.V.3, 4 , Bulushova N.V.3 , Zavilgelsky G.B.3 , Kotova V.Y.3 , Manukhov I.V.3, 4
Springer New York LLC
  • 1 Laboratory of Combined Treatment, Laboratory of Cell Immunity, N.N. Blokhin Cancer Research Center, Moscow, Russian Federation
  • 2 Department of Biochemistry, Peoples’ Friendship University of Russia (RUDN University), Moscow, Russian Federation
  • 3 State Research Institute of Genetics and Selection of Industrial Microorganisms, Moscow, Russian Federation
  • 4 Laboratory of Molecular Genetics, Moscow Institute of Physics and Technology, Dolgoprudny, Moscow, Region, Russian Federation
Ключевые слова
Cisplatin; Combined treatment; Doxorubicin; Methioninase; Methionine gamma lyase
Дата создания
Дата изменения
Постоянная ссылка